Tectonic Therapeutic Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
60
IPO date
Jun 21, 2018

AVROBIO Inc. is a biotechnology company that develops gene therapies for rare inherited diseases. Its core idea is to take a patient’s own blood-forming stem cells, add a working copy of a faulty gene in the lab, and put the corrected cells back into the body. The goal is to treat the root cause of the disease rather than manage symptoms with lifelong medicines.

Because it is a drug developer, AVROBIO does not sell a broad catalog of products to everyday consumers. Its work is aimed at patients with serious single-gene disorders, and any future sales would likely flow through hospitals, specialty treatment centers, and healthcare payers after regulatory approval. Like many biotech companies at this stage, it has mainly depended on financing, research partnerships, and other drug-development funding rather than product sales.

What makes AVROBIO’s model different is the treatment style it is pursuing. Instead of making a drug that patients take repeatedly, it is trying to create one-time or infrequent gene therapies based on a patient’s own cells. That makes the science more complex and expensive than standard medicines, but it also gives the company a chance to target diseases where existing treatments are limited or only manage symptoms.

Tectonic Therapeutic Inc Investor Relations

Address
490 Arsenal Way, Suite 210
Watertown, Massachusetts
United States of America

Business Segments

Gene therapy development

AVROBIO develops gene therapies that use a patient’s own stem cells and modified genes to treat rare inherited diseases. The company focuses on creating and testing these treatments in clinical and preclinical programs.

Customers and revenue model

Management

Dr. Alise S. Reicin M.D., Ph.D.

President, CEO, Secretary & Director

Biography unavailable

Dr. Marcella K. Ruddy M.D., M.S.

Chief Medical Officer

Biography unavailable

Mr. Daniel Lochner M.B.A.

Chief Financial Officer

Biography unavailable

Dr. Peter McNamara Ph.D.

Chief Scientific Officer

Biography unavailable

Mr. Barry Rubenstein M.S.

Senior Vice President of People & Culture

Biography unavailable

Mr. Anthony Muslin M.D.

Chief Development Officer

Biography unavailable

Dr. Marc Schwabish Ph.D.

Chief Business Officer

Biography unavailable

John Diener

Senior Vice President of Antibody Engineering & Protein Sciences

Biography unavailable

1 / 8